CoChat

Impact of peripheral myeloid cells on amyloid-β pathology in Alzheimer’s disease–like mice

Open access
Prokop, Stefan, Miller, Kelly R., Drost, Natalia, Handrick, Susann, Mathur, Vidhu, Luo, Jian, Wegner, Anja, Wyss-Coray, Tony, Heppner, Frank L. · 2015 · Journal of Experimental Medicine

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Although central nervous system–resident microglia are believed to be ineffective at phagocytosing and clearing amyloid-β (Aβ), a major pathological hallmark of Alzheimer’s disease (AD), it has been suggested that peripheral myeloid cells constitute a heterogeneous cell population with greater Aβ-clearing capabilities. Here, we demonstrate that the conditional ablation of resident microglia in CD11b-HSVTK (TK) mice is followed by a rapid repopulation of the brain by peripherally derived myeloid cells. We used this system to directly assess the ability of peripheral macrophages to reduce Aβ plaque pathology and therefore depleted and replaced the pool of resident microglia with peripherally derived myeloid cells in Aβ-carrying APPPS1 mice crossed to TK mice (APPPS1;TK). Despite a nearly complete exchange of resident microglia with peripheral myeloid cells, there was no significant change in Aβ burden or APP processing in APPPS1;TK mice. Importantly, however, newly recruited peripheral myeloid cells failed to cluster around Aβ deposits. Even additional anti-Aβ antibody treatment aimed at engaging myeloid cells with amyloid plaques neither directed peripherally derived myeloid cells to amyloid plaques nor altered Aβ burden. These data demonstrate that mere recruitment of peripheral myeloid cells to the brain is insufficient in substantially clearing Aβ burden and suggest that specific additional triggers appear to be required to exploit the full potential of myeloid cell–based therapies for AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20150479

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Peripheral origin of repopulating myeloid cells in nonchimeric microglia-depleted parabiotic mice. TK and Act.GFP mice were surgically connected to establish a joined circulatory system. Upon establishment of blood chimerism in both partners (2 wk), icv GCV was administered to the TK partners for 10 d to deplete microglia. Mice were sacrificed 24 d after starting GCV treatment. (a and b) Representative images of GFP-positive cells (middle columns) in microglia-depleted (GCV-treated) TK mice (bottom rows), WT controls (top rows), or non-microglia–depleted aCSF-treated TK controls (middle rows). Shown are cortical (a) or hippocampal (b) brain regions stained for Iba1 (left columns) or GFP (middle columns), as well as merged images (right columns). Bars, 200 µm. (c) Flow cytometric analysis of GFP+ cells in blood of parabiotic pairs. (d and e) Stereological quantification of Iba1-positive cells (d; *, P = 0.03; n = 5 per group) and GFP-positive cells (e; *, P = 0.02; n = 5 per group) in brains of mice described in a–c. All data are displayed as mean ± SEM.
Figure 1. Peripheral origin of repopulating myeloid cells in nonchimeric microglia-depleted parabiotic mice. TK and Act.GFP mice were surgically connected to establish a joined circulatory system. Upon establishment of blood chimerism in both partners (2 wk), icv GCV was administered to the TK partners for 10 d to deplete microglia. Mice were sacrificed 24 d after starting GCV treatment. (a and b) Representative images of GFP-positive cells (middle columns) in microglia-depleted (GCV-treated) TK mice (bottom rows), WT controls (top rows), or non-microglia–depleted aCSF-treated TK controls (middle rows). Shown are cortical (a) or hippocampal (b) brain regions stained for Iba1 (left columns) or GFP (middle columns), as well as merged images (right columns). Bars, 200 µm. (c) Flow cytometric analysis of GFP+ cells in blood of parabiotic pairs. (d and e) Stereological quantification of Iba1-positive cells (d; *, P = 0.03; n = 5 per group) and GFP-positive cells (e; *, P = 0.02; n = 5 per group) in brains of mice described in a–c. All data are displayed as mean ± SEM.CC BY-NC-SA · PubMed Central
Figure 2. Peripheral myeloid cells do not affect Aβ pathology in microglia-depleted APPPS1;TK+/− mice. (a) Representative images of Iba1 immunohistochemistry (blue) in peripheral myeloid cell–repopulated APPPS1;TK+/− mice (bottom) and similarly GCV-treated APPPS1;TK−/− control mice (top). (b) Stereological quantification of Iba1-positive cells (n = 5–8 per group). (c) Overview images of Iba1 immunohistochemistry (blue). (d) qPCR analysis of Cd11b, Cx3cr1, Hexb, P2ry12, and Trem2 from whole brain tissue of APPPS1;TK+/− mice compared with APPPS1;TK−/− controls (*, P = 0.03; **, P = 0.007; n = 6 per group). (e) Representative images of 4G8 immunohistochemistry. (f) Stereological quantification of the area covered by 4G8-positive plaques (n = 6–9 per group). (g and h) Congo red staining (g) and stereological quantification (h) of the area covered by Congo red–positive plaques (n = 6–9 per group). Bars: (a) 20 µm; (c, e, and g) 100 µm. (i) Amount of soluble and insoluble Aβ40 and Aβ42 and total Aβ40 and Aβ42 calculated from individual fractions measured by Meso Scale Diagnostics (measurements performed in duplicate from n = 5 biological replicates per group). (j) Representative Western blot images of APP, APPCTFβ, and APPCTFα in SDS fractions from brain homogenates described in i (6E10 detection; left) and representative quantification of Western blots (right; result representative for four independent experiments). All p-values >0.05 unless otherwise stated. All data are represented as mean ± SEM. All mice were treated icv for 10 d with GCV followed by a 28-d period without GCV administration.
Figure 2. Peripheral myeloid cells do not affect Aβ pathology in microglia-depleted APPPS1;TK+/− mice. (a) Representative images of Iba1 immunohistochemistry (blue) in peripheral myeloid cell–repopulated APPPS1;TK+/− mice (bottom) and similarly GCV-treated APPPS1;TK−/− control mice (top). (b) Stereological quantification of Iba1-positive cells (n = 5–8 per group). (c) Overview images of Iba1 immunohistochemistry (blue). (d) qPCR analysis of Cd11b, Cx3cr1, Hexb, P2ry12, and Trem2 from whole brain tissue of APPPS1;TK+/− mice compared with APPPS1;TK−/− controls (*, P = 0.03; **, P = 0.007; n = 6 per group). (e) Representative images of 4G8 immunohistochemistry. (f) Stereological quantification of the area covered by 4G8-positive plaques (n = 6–9 per group). (g and h) Congo red staining (g) and stereological quantification (h) of the area covered by Congo red–positive plaques (n = 6–9 per group). Bars: (a) 20 µm; (c, e, and g) 100 µm. (i) Amount of soluble and insoluble Aβ40 and Aβ42 and total Aβ40 and Aβ42 calculated from individual fractions measured by Meso Scale Diagnostics (measurements performed in duplicate from n = 5 biological replicates per group). (j) Representative Western blot images of APP, APPCTFβ, and APPCTFα in SDS fractions from brain homogenates described in i (6E10 detection; left) and representative quantification of Western blots (right; result representative for four independent experiments). All p-values >0.05 unless otherwise stated. All data are represented as mean ± SEM. All mice were treated icv for 10 d with GCV followed by a 28-d period without GCV administration.CC BY-NC-SA · PubMed Central
Figure 3. Anti-Aβ antibodies fail to specifically promote plaque association or clearance by peripheral myeloid cells. (a) Representative images of Iba1 immunohistochemistry (blue) combined with pFTAA staining (green) are shown. (b) Stereological quantification of number of Iba1-positive cells (left; n = 5–6 per group) and quantification of Iba1-positive cell bodies per pFTAA area (right; n = 5–6 per group; ***, P = 0.0005). (c and e) Representative images of 4G8 immunohistochemistry (c) and Congo red staining (e). (a, c, and e) Bars, 100 µm. (d) Stereological quantification of the area covered by 4G8-positive plaques (top; **, P = 0.009) and number of 4G8-positive plaques (bottom; *, P = 0.02; n = 5–7 per group). (f) Stereological quantification of the number of Congo red–positive plaques (*, P = 0.02; n = 5–7 per group). (g) Amount of soluble and insoluble Aβ40 and Aβ42 and total Aβ40 and Aβ42 calculated from individual protein fractions (*, P = 0.04; measurements performed in duplicate from n = 5–7 biological replicates per group). (h) Representative image of Western blot analyses of APP, APPCTFβ, and APPCTFα in SDS-extracted brain fractions (APPct detection; left) and representative quantification of Western blots (right; result representative of six independent experiments). All data are represented as mean ± SEM.
Figure 3. Anti-Aβ antibodies fail to specifically promote plaque association or clearance by peripheral myeloid cells. (a) Representative images of Iba1 immunohistochemistry (blue) combined with pFTAA staining (green) are shown. (b) Stereological quantification of number of Iba1-positive cells (left; n = 5–6 per group) and quantification of Iba1-positive cell bodies per pFTAA area (right; n = 5–6 per group; ***, P = 0.0005). (c and e) Representative images of 4G8 immunohistochemistry (c) and Congo red staining (e). (a, c, and e) Bars, 100 µm. (d) Stereological quantification of the area covered by 4G8-positive plaques (top; **, P = 0.009) and number of 4G8-positive plaques (bottom; *, P = 0.02; n = 5–7 per group). (f) Stereological quantification of the number of Congo red–positive plaques (*, P = 0.02; n = 5–7 per group). (g) Amount of soluble and insoluble Aβ40 and Aβ42 and total Aβ40 and Aβ42 calculated from individual protein fractions (*, P = 0.04; measurements performed in duplicate from n = 5–7 biological replicates per group). (h) Representative image of Western blot analyses of APP, APPCTFβ, and APPCTFα in SDS-extracted brain fractions (APPct detection; left) and representative quantification of Western blots (right; result representative of six independent experiments). All data are represented as mean ± SEM.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 116

Metadata

Authors
Prokop, S., Miller, K. R., Drost, N., Handrick, S., Mathur, V., Luo, J., Wegner, A., Wyss-Coray, T., & Heppner, F. L.
Affiliations
  • Charité – Universitätsmedizin Berlin (DE)
  • VA Palo Alto Health Care System (US)
  • Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305 2
  • NeuroCure Cluster of Excellence (DE)
Corresponding author
Heppner, Frank L.
Venue
Journal of Experimental Medicine
Published
2015-10-12
Volume
212
Issue
11
Pages
1811-1818
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W1922340941
Cited by
116
References
28
Citations by year
2026: 4 · 2025: 6 · 2024: 8 · 2023: 11 · 2022: 7 · 2021: 6 · 2020: 13 · 2019: 10 · 2018: 19 · 2017: 18 · 2016: 11 · 2015: 3
FWCI
12.53
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (acceptedVersion, cc-by-nc-sa)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • Deutsche Forschungsgemeinschaft (SFB TRR 43, NeuroCure EXC257, EXC257)
  • Bundesministerium für Bildung und Forschung
  • Berlin Institute of Health
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
Keywords
microglia, amyloid-beta clearance, Alzheimer's disease, APP/PS1 mice, myeloid cell recruitment, anti-amyloid antibodies, amyloid plaques, APP processing
MeSH terms
Alzheimer Disease, Animals, Cell Movement, Disease Models, Animal, Male, Vaccination, Ganciclovir, Amyloid beta-Peptides, Microglia, Myeloid Cells, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.